System and method for prostrate treatment
AssigneeResurge Therapeutics, Inc.
InventorsOlof Mikael TROLLSAS, John J. STANKUS, Shahram Shawn GHOLAMI
Life of this patent
Estimating the term…
Abstract
A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.
Claims20
A system for treatment of benign prostatic hyperplasia tissue, comprising:
- a sustained release formulation (SRF) comprising a cytostatic or cytotoxic drug, and
- an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the SRF to the target tissue of the prostate.
A system for treatment of benign prostatic hyperplasia tissue, comprising:
- a sustained release formulation comprising an alpha blocker, and/or a 5-alpha reductase inhibitor, and
- an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate.
Dependencies are inferred from the claim text.